| Literature DB >> 35854065 |
Cui Liu1, JunLei Wang1, YaJuan Zheng1, Yue Zhu1, ZhengHang Zhou2, ZhaoYuan Liu1, ChangDong Lin3, YaoYing Wan1, YaTing Wen1, ChunYe Liu1, MengYa Yuan1, Yi Arial Zeng1,2, ZhanJun Yan4, GaoXiang Ge5,6, JianFeng Chen7,8.
Abstract
Tumor metastasis is the leading cause of cancer-associated mortality. Unfortunately, the underlying mechanism of metastasis is poorly understood. Expression of legumain (LGMN), an endo-lysosomal cysteine protease, positively correlates with breast cancer metastatic progression and poor prognosis. Here, we report that LGMN is secreted in the zymogen form by motile breast cancer cells. Through binding to cell surface integrin αvβ3 via an RGD motif, the autocrine pro-LGMN activates FAK-Src-RhoA signaling in cancer cells and promotes cancer cell migration and invasion independent of LGMN protease activity. Either silencing LGMN expression or mutationally abolishing pro-LGMN‒αvβ3 interaction significantly inhibits cancer cell migration and invasion in vitro and breast cancer metastasis in vivo. Finally, we developed a monoclonal antibody against LGMN RGD motif, which blocks pro-LGMN‒αvβ3 binding, and effectively suppresses cancer cell migration and invasion in vitro and breast cancer metastasis in vivo. Thus, disruption of pro-LGMN‒integrin αvβ3 interaction may be a potentially promising strategy for treating breast cancer metastasis.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35854065 DOI: 10.1038/s41388-022-02409-4
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 8.756